Last 35 quarters of trend data · Healthcare · Life Science Tools
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -55.13 | — | — | — | — | 27.87 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 17.42 | 13.56 | 6.62 | 4.67 | 4.29 | 5.86 | 6.31 | 7.75 | 7.74 | 8.79 | 6.58 | 7.41 | 4.33 | 4.58 | 3.56 | 6.19 | 8.65 | 8.77 | 13.72 | 22.98 | 34.77 |
| — | +131.5% | +4.9% | -39.7% | -44.5% | -33.4% | -4.1% | +4.5% | +78.5% | +92.1% | +85.0% | +19.6% | -49.9% | -47.8% | -74.1% | -73.0% | -75.1% | -81.2% | -71.6% | -60.2% | +32.6% | |
| P/B Ratio | 15.27 | 14.40 | 6.44 | 4.25 | 3.60 | 4.71 | 5.32 | 6.03 | 5.55 | 5.83 | 3.54 | 3.59 | 1.86 | 1.77 | 1.22 | 1.80 | 2.51 | 2.40 | 3.06 | 6.17 | 9.09 |
| — | +206.1% | +21.1% | -29.6% | -35.2% | -19.3% | +50.3% | +67.9% | +197.9% | +228.7% | +191.0% | +99.5% | -25.9% | -26.0% | -60.2% | -70.8% | -72.4% | -77.6% | -68.9% | -39.5% | -10.2% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | 25.84 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 50.7% | 52.8% | 51.6% | 52.0% | 51.3% | 53.4% | 49.6% | 48.3% | 45.1% | 43.3% | 41.0% | 40.5% | 36.6% | 34.4% | 30.8% | 45.7% | 44.9% | 44.8% | 38.3% | 35.6% | 40.7% |
| — | -1.2% | +4.0% | +7.8% | +13.8% | +23.3% | +21.0% | +19.2% | +23.2% | +26.0% | +33.3% | -11.4% | -18.4% | -23.3% | -19.6% | +28.4% | +10.2% | +11.4% | -2.0% | +0.3% | -11.1% | |
| Operating Margin | -36.2% | -30.6% | -34.9% | -31.7% | -30.2% | -31.4% | -44.8% | -39.1% | -42.5% | -109.2% | -64.9% | -65.7% | -74.9% | -95.4% | -102.4% | -82.3% | -99.2% | -109.0% | -126.3% | -133.1% | -104.9% |
| — | +2.3% | +22.0% | +18.8% | +28.9% | +71.3% | +31.0% | +40.6% | +43.2% | -14.5% | +36.6% | +20.1% | +24.6% | +12.5% | +18.9% | +38.2% | +5.4% | +9.4% | -3.7% | -14.3% | -42.0% | |
| Net Margin | -20.6% | -29.6% | -39.8% | -29.4% | -27.4% | 21.2% | -42.4% | -35.6% | -40.9% | -105.0% | -60.4% | -60.2% | -69.1% | -90.0% | -98.3% | -77.1% | -89.2% | -107.8% | -126.1% | -108.4% | -108.7% |
| — | -239.5% | +6.2% | +17.4% | +33.0% | +120.2% | +29.8% | +40.8% | +40.8% | -16.7% | +38.5% | +22.0% | +22.6% | +16.5% | +22.0% | +28.9% | +17.9% | +5.7% | -3.7% | +7.2% | -44.9% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.4% | -7.8% | -9.7% | -6.6% | -5.7% | 4.4% | -8.8% | -6.8% | -7.2% | -16.3% | -7.9% | -7.1% | -7.2% | -8.4% | -8.2% | -5.4% | -6.3% | -7.2% | -8.1% | -7.5% | -6.9% |
| — | -275.2% | -10.1% | +3.5% | +20.6% | +127.3% | -11.0% | +4.0% | +0.4% | -93.1% | +3.0% | -30.1% | -13.7% | -17.3% | -0.1% | +27.9% | +8.3% | -9.9% | -34.5% | -11.8% | +2.5% | |
| ROA | -12.4% | -5.2% | -6.7% | -4.8% | -4.2% | 3.3% | -6.5% | -5.2% | -5.5% | -12.8% | -6.3% | -5.7% | -5.8% | -6.9% | -6.7% | -4.5% | -5.3% | -6.0% | -6.7% | -6.1% | -5.8% |
| — | -258.0% | -2.6% | +7.7% | +23.7% | +125.8% | -3.1% | +9.3% | +5.1% | -85.0% | +5.5% | -27.5% | -10.7% | -14.0% | +0.1% | +27.0% | +8.9% | -5.9% | -21.9% | -2.2% | +4.1% | |
| ROIC | -26.9% | -6.4% | -6.3% | -5.4% | -5.7% | -6.8% | -9.9% | -8.0% | -8.1% | -17.9% | -8.9% | -8.3% | -8.6% | -9.9% | -9.2% | -6.5% | -8.3% | -8.7% | -8.7% | -12.2% | -15.8% |
| — | +5.8% | +36.6% | +33.0% | +28.8% | +62.0% | -11.4% | +3.7% | +6.2% | -81.2% | +3.1% | -28.0% | -3.7% | -13.9% | -5.3% | +46.9% | +47.7% | +38.8% | +12.6% | -49.8% | -101.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.29 | 0.21 | 0.21 | 0.40 | 0.29 | 0.16 | 0.18 | 0.18 | 0.18 | 0.18 | 0.16 | 0.16 | 0.15 | 0.14 | 0.13 | 0.13 | 0.12 | 0.10 | 0.09 | 0.12 | 0.11 |
| — | +28.5% | +15.4% | +122.5% | +61.4% | -7.9% | +14.3% | +16.4% | +19.2% | +25.5% | +23.2% | +23.7% | +25.5% | +47.7% | +40.4% | +8.1% | +11.0% | -8.3% | +77.5% | +118.1% | +1.2% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.64 | 2.67 | 2.70 | 3.78 | 3.64 | 3.90 | 4.51 | 4.96 | 4.88 | 4.91 | 5.51 | 5.98 | 5.79 | 6.12 | 6.79 | 6.46 | 6.58 | 6.73 | 7.85 | 4.81 | 8.67 |
| — | -31.5% | -40.3% | -23.8% | -25.4% | -20.5% | -18.1% | -17.1% | -15.6% | -19.8% | -18.8% | -7.4% | -12.1% | -9.1% | -13.6% | +34.4% | -24.1% | -36.0% | -47.8% | -71.9% | -6.7% | |
| Quick Ratio | 3.33 | 2.38 | 2.42 | 3.37 | 3.33 | 3.60 | 4.24 | 4.62 | 4.54 | 4.52 | 5.06 | 5.51 | 5.35 | 5.62 | 6.23 | 5.93 | 6.15 | 6.27 | 7.32 | 4.31 | 8.16 |
| — | -34.0% | -42.9% | -27.1% | -26.7% | -20.2% | -16.3% | -16.1% | -15.0% | -19.6% | -18.8% | -7.1% | -13.0% | -10.4% | -14.9% | +37.7% | -24.7% | -38.1% | -50.0% | -74.3% | -8.8% | |
| Interest Coverage | — | — | — | — | — | — | -272.80 | -1311.38 | -1197.34 | — | — | — | -46464.00 | -56772.00 | -29239.00 | -41747.00 | -1953.73 | — | -2096.14 | -2151.62 | -491.78 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 35 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TWST stock.
Twist Bioscience Corporation's current P/E is -55.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Twist Bioscience Corporation's current operating margin is -36.2%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Twist Bioscience Corporation's business trajectory between earnings reports.